Publications by Dr David Sheridan - ePrints

Browsing publications by Dr David Sheridan.

Newcastle Authors	Title	Year
Dr David Sheridan Professor Stuart McPherson	National study of NAFLD management identifies variation in delivery of care in the UK between 2019-2022	2023
Professor David Jones Dr David Sheridan	A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis	2022
Dr David Sheridan Dr Daniel Felmlee Dr Simon Bridge Emeritus Professor Margaret Bassendine	Infection with the hepatitis C virus causes viral genotype-specific differences in cholesterol metabolism and hepatic steatosis	2022
Dr David Sheridan Professor Quentin Anstee Professor Stuart McPherson	Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey	2017
Emeritus Professor Margaret Bassendine Dr Soren Nielsen Dr Simon Bridge Dr Daniel Felmlee Dr David Sheridan et al.	Hepatitis C virus and atherosclerosis: A legacy after virologic cure?	2017
Dr Luca Miele Dr David Sheridan	Diverse Impacts of the rs58542926 E167K Variant in TM6SF2 on Viral and Metabolic Liver Disease Phenotypes	2016
Dr David Sheridan	FibroGENE: A gene-based model for staging liver fibrosis	2016
Dr David Sheridan Fiona Fenwick Emeritus Professor Margaret Bassendine	Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection	2016
Professor Quentin Anstee Dr David Sheridan	Staging fibrosis and excluding advanced fibrosis in patients with NAFLD: comparison of non-invasive markers in an interim analysis from a prospective multicentre study	2016
Dr David Sheridan Professor Margaret Bassendine	Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease	2015
Dr David Sheridan Dr Simon Bridge Dr Daniel Felmlee Emeritus Professor Margaret Bassendine	Lipidomics analysis of fasting serum identifies novel lipid biomarkers specific for HCV genotype 3 and genotype 1 chronic hepatitis C virus infection	2015
Dr Simon Bridge Dr David Sheridan Dr Daniel Felmlee Fiona Fenwick Dr Clare Lanyon et al.	PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: Evidence for genotype-specific regulation of lipoprotein metabolism	2015
Dr David Sheridan Dr Simon Bridge Dr Daniel Felmlee Dr R Neely Emeritus Professor Margaret Bassendine et al.	Depressive symptoms in chronic hepatitis C are associated with plasma apolipoprotein E deficiency	2014
Dr David Sheridan Emeritus Professor Margaret Bassendine	Hepatitis C lipoviral particle levels are associated with spontaneous clearance of acute infection	2014
Dr David Sheridan	IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection	2014
Dr David Sheridan Dr Simon Bridge Dr Daniel Felmlee Fiona Fenwick Dr R Neely et al.	Omega-3 fatty acids and/or fluvastatin in hepatitis C prior non-responders to combination antiviral therapy - a pilot randomised clinical trial	2014
Professor Margaret Bassendine Dr David Sheridan Jaime Jonsson	CCR5-Δ32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection	2013
Dr David Sheridan Dr R Neely Professor Margaret Bassendine	Hepatitis C virus and lipids in the era of direct acting antivirals (DAAs)	2013
Professor Margaret Bassendine Dr David Sheridan Dr Simon Bridge Dr Daniel Felmlee Dr R Neely et al.	Lipids and HCV	2013
Dr David Sheridan Dr Daniel Felmlee Dr Simon Bridge Fiona Fenwick Emeritus Professor Geoffrey Toms et al.	Metabolic Syndrome and Insulin Resistance are Associated with Maximum Hepatitis C Lipoviral Particles in Genotype 1 Infection	2013
Dr David Sheridan Dr Simon Bridge Dr Daniel Felmlee Fiona Fenwick Professor Margaret Bassendine et al.	Omega-3 Fatty Acids and/or Fluvastatin in Hepatitis C Prior Non-Responders to Combination Anti-Viral Therapy - A Pilot Randomised Clinical Trial	2013
Dr David Sheridan Dr Simon Bridge Dr Daniel Felmlee Emeritus Professor Geoffrey Toms Dr R Neely et al.	Apolipoprotein-E and hepatitis C lipoviral particles in genotype 1 infection: Evidence for an association with interferon sensitivity	2012
Professor Margaret Bassendine Dr David Sheridan	IL28B, HLA-C, and KIR Variants Additively Predict Response to Therapy in Chronic Hepatitis C Virus Infection in a European Cohort: A Cross-Sectional Study	2011
Dr Simon Bridge Dr David Sheridan Dr Daniel Felmlee Emeritus Professor Geoffrey Toms Professor Margaret Bassendine et al.	Apolipoprotein E and low-density, apolipoprotein B associated lipoviral particles in chronic Hepatitis C infection: Evidence for genotype-specific modulation of lipid pathways	2011
Professor Margaret Bassendine Dr David Sheridan Dr Daniel Felmlee Dr Simon Bridge Emeritus Professor Geoffrey Toms et al.	HCV and the hepatic lipid pathway as a potential treatment target	2011
Dr Daniel Felmlee Dr David Sheridan Dr Simon Bridge Emeritus Professor Geoffrey Toms Professor Margaret Bassendine et al.	Use of intralipid infusion to analyse apolipoprotein B (APOB) and HCV RNA kinetics in chronic infection	2011
Dr David Sheridan Professor Kim Bartlett Dr Daniel Felmlee Dr Simon Bridge Emeritus Professor Geoffrey Toms et al.	Hypocholesterolaemia in chronic hepatitis C genotype 3 infection is due to both reduced cholesterol production and increased LDL clearance	2010
Dr David Sheridan Professor Kim Bartlett Dr Daniel Felmlee Dr Simon Bridge Emeritus Professor Geoffrey Toms et al.	Hypocholesterolaemia in chronic Hepatitis C virus (HCV) infection - Reduced production or increased LDL clearance?	2010
Dr Simon Bridge Dr David Sheridan Dr Daniel Felmlee Dr Soren Nielsen Dr R Neely et al.	Insulin resistance and low-density apolipoprotein B-associated lipoviral particles in hepatitis C virus genotype 1 infection	2010
Dr Simon Bridge Dr David Sheridan Dr Daniel Felmlee Dr Soren Nielsen Dr R Neely et al.	Insulin resistance correlates with low density hepatitis C virus particles in genotype 1 infection	2010
Dr Daniel Felmlee Dr David Sheridan Dr Simon Bridge Dr Soren Nielsen Emeritus Professor Geoffrey Toms et al.	Intravascular Transfer Contributes to Postprandial Increase in Numbers of Very-Low-Density Hepatitis C Virus Particles	2010
Dr Simon Bridge Dr David Sheridan Dr Daniel Felmlee Emeritus Professor Geoffrey Toms Dr R Neely et al.	Low density Hepatitis C virus particles (lipoviral particles) associate with insulin resistance in genotype 1 infection	2010
Dr Simon Bridge Dr David Sheridan Dr Daniel Felmlee Emeritus Professor Geoffrey Toms Professor Margaret Bassendine et al.	Measurement of low-density Apolipoprotein B associated lipoviral particles in hepatitis C virus genotype 1 infection is more clinically relevant than total viral load	2010
Dr Daniel Felmlee Dr David Sheridan Dr Simon Bridge Emeritus Professor Geoffrey Toms Professor Margaret Bassendine et al.	The HCV life-cycle in the vascular compartment	2010
Dr Monique Welten Professor Margaret Bassendine Dr David Sheridan Dr James George	IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy	2009
Dr Simon Bridge Dr David Sheridan Dr Daniel Felmlee Dr Soren Nielsen Emeritus Professor Geoffrey Toms et al.	Apolipoprotein B Associated Hepatitis C Virus (HCV): A Minority of Total Viral Load in Patients with Chronic HCV	2009
Dr David Sheridan Dr David Price Dr Matthias Schmid Emeritus Professor Geoffrey Toms Dr Peter Donaldson et al.	Apolipoprotein B-associated cholesterol is a determinant of treatment outcome in patients with chronic hepatitis C virus infection receiving anti-viral agents interferon-alpha and ribavirin	2009
Dr Daniel Felmlee Dr Simon Bridge Dr David Sheridan Dr Soren Nielsen Emeritus Professor Geoffrey Toms et al.	Large and Buoyant Hepatitis C Virus (HCV) Particles Surge after Patients Consume a High-Fat Meal	2009
Dr David Sheridan Dr David Price Dr Matthias Schmid Emeritus Professor Geoffrey Toms	Apolipoprotein B associated cholesterol level is a predictor of response to therapy in chronic hepatitis C	2008